{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-000605","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.697576+00:00","generated_at":"2026-06-02T08:49:36.497627+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunic reports Q1 2024 net loss $29.6M; cash extended into Q3 2025 on $240M private placement","bullets":["Net loss $29.6M ($0.30/share) vs $25.3M ($0.58) in Q1 2023; R&D spend $18.7M, down 18% YoY.","Cash $97.3M at March 31, 2024; runway into Q3 2025 after $240M private placement ($80M initial tranche).","Phase 2 CALLIPER (progressive MS) top-line data expected April 2025; Phase 3 ENSURE readout Q2 2026 and H2 2026.","Received fourth US patent for vidofludimus calcium (composition of matter) protecting into 2041.","IMU-856 preparing for phase 2 in celiac disease after positive phase 1b data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-000605","json":"https://secwatch.observer/filing/0001193805-24-000605.json","markdown":"https://secwatch.observer/filing/0001193805-24-000605.md","text":"https://secwatch.observer/filing/0001193805-24-000605.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000605/0001193805-24-000605-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000605/e663589_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T08:49:36.497627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f8c9761e5c4134c824d0f7cd98b6c74d69c989a2","claim":"IMMUNIC, INC. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On May 8, 2024, Immunic, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a corporate update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000605/0001193805-24-000605-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}